Teva has announced a collaboration deal with Royalty Pharma that will see the firm “provide R&D and funding support of up to $125m” for the development of Teva’s olanzapine long-acting injectable, known by the development codename TEV-‘749.
Teva Gets Investment From Royalty On Olanzapine LAI
Follows Successful Launch Of Uzedy LAI Risperidone In The US Earlier This Year
Teva has announced a new investment from Royalty Pharma in its long-acting injectable formulation of olanzapine that is being developed for the US market with partner MedinCell.
